New hope for Hard-to-Treat myeloma: cevostamab trial underway

NCT ID NCT05535244

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This study tests a drug called cevostamab in 90 people with multiple myeloma that has returned or not responded to prior treatments, including BCMA-targeted therapies. Participants receive cevostamab by IV every 3 weeks. The goal is to see if the drug can shrink tumors and how safe it is. Side effects like cytokine release syndrome will be managed with another drug, tocilizumab.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cevostamab (a drug given by IV infusion)
What this could lead to: If successful, cevostamab could offer a new treatment option for people with multiple myeloma that has stopped responding to other BCMA-targeted therapies.
What could go wrong: This is an early-phase trial with only 90 participants, so results may not apply to everyone. Side effects like cytokine release syndrome are possible and will be managed with tocilizumab.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

A.O. Città della Salute e della Scienza D - Osp. S. Giov. Battista Molinette

Turin, Piedmont, 10126, Italy
APHP - Hospital Saint Louis

Paris, 75475, France
Asst Papa Giovanni Xxiii

Bergamo, Lombardy, 24127, Italy
CHU NANTES - Hôtel Dieu

Nantes, 44093, France
CHU de Poitiers - La Miletrie

Poitiers, 86021, France
Calvary Mater Newcastle

Waratah, New South Wales, 2298, Australia
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Fond. IRCCS Istituto Nazionale Tumori

Milan, Lombardy, 20133, Italy
Hadassah Ein Karem Hospital

Jerusalem, 9112001, Israel
Hospital Clínic i Provincial

Barcelona, 08036, Spain
Hospital Univ. 12 de Octubre

Madrid, 28041, Spain
Hunstman Cancer Institute

Salt Lake City, Utah, 84112, United States
Icahn School of Medicine at Mount Sinai (ISMMS)

New York, New York, 10029, United States
Klinik der Uni zu Köln

Cologne, 50924, Germany
Mayo Clinic - Rochester

Rochester, Minnesota, 55905, United States
Mayo Clinic-Jacksonville

Jacksonville, Florida, 32224, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Policlinico S.Orsola-Malpighi

Bologna, Emilia-Romagna, 40138, Italy
Sheba Medical Center

Ramat Gan, 5262100, Israel
Sourasky Medical Centre

Tel Aviv, 6423906, Israel
St Vincent's Hospital Melbourne

Fitzroy, Victoria, 3065, Australia
Tennessee Oncology - Nashville

Nashville, Tennessee, 37203, United States
UZ Leuven Gasthuisberg

Leuven, 3000, Belgium
University of Colorado

Aurora, Colorado, 80045-2517, United States
University of Maryland Greenebaum Cancer Center

Baltimore, Maryland, 21201, United States
Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II

Hamburg, 20246, Germany
Universitätsklinikum Würzburg

Würzburg, 97080, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.